{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:18:05Z","timestamp":1792207085651,"version":"4.4.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,4]],"date-time":"2014-11-04T00:00:00Z","timestamp":1415059200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2407-14-808","type":"journal-article","created":{"date-parts":[[2014,11,4]],"date-time":"2014-11-04T12:03:45Z","timestamp":1415102625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization"],"prefix":"10.1186","volume":"14","author":[{"given":"Arabella","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele F","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas B","family":"Blackburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne L","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marketa","family":"Skala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate H","family":"Brettingham-Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,4]]},"reference":[{"key":"4994_CR1","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/S0360-3016(03)00632-1","volume":"57","author":"DA Kuban","year":"2003","unstructured":"Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL: Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003, 57: 915-928. 10.1016\/S0360-3016(03)00632-1.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4994_CR2","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/cncr.20093","volume":"100","author":"D Khuntia","year":"2004","unstructured":"Khuntia D, Reddy CA, Mahadevan A, Klein EA, Kupelian PA: Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect?. Cancer. 2004, 100: 1283-1292. 10.1002\/cncr.20093.","journal-title":"Cancer"},{"key":"4994_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.eururo.2011.09.027","volume":"61","author":"L Budaus","year":"2012","unstructured":"Budaus L, Bolla M, Bossi A, Cozzarini C, Crook J, Widmark A, Wiegel T: Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol. 2012, 61: 112-127. 10.1016\/j.eururo.2011.09.027.","journal-title":"Eur Urol"},{"key":"4994_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1748-717X-9-42","volume":"9","author":"M Anwar","year":"2014","unstructured":"Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M, Gottschalk A: Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. Radiat Oncol. 2014, 9: 42-10.1186\/1748-717X-9-42.","journal-title":"Radiat Oncol"},{"key":"4994_CR5","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Van Cutsem","year":"2011","unstructured":"Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011, 29: 2011-2019. 10.1200\/JCO.2010.33.5091.","journal-title":"J Clin Oncol"},{"key":"4994_CR6","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011, 364: 2507-2516. 10.1056\/NEJMoa1103782.","journal-title":"N Engl J Med"},{"key":"4994_CR7","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","volume":"17","author":"MA Cobleigh","year":"1999","unstructured":"Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999, 17: 2639-2648.","journal-title":"J Clin Oncol"},{"key":"4994_CR8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","volume":"157","author":"VA Moyer","year":"2012","unstructured":"Moyer VA: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012, 157: 120-134. 10.7326\/0003-4819-157-2-201207170-00459.","journal-title":"Ann Intern Med"},{"key":"4994_CR9","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/S0022-5347(01)67331-2","volume":"153","author":"BW Corn","year":"1995","unstructured":"Corn BW, Hanks GE, Lee WR, Bonin SR, Hudes G, Schultheiss T: Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformal radiotherapy. J Urol. 1995, 153: 1855-1859. 10.1016\/S0022-5347(01)67331-2.","journal-title":"J Urol"},{"key":"4994_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.7326\/0003-4819-149-3-200808050-00009","volume":"149","author":"K Lin","year":"2008","unstructured":"Lin K, Lipsitz R, Miller T, Janakiraman S, Force USPST: Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med. 2008, 149: 192-199. 10.7326\/0003-4819-149-3-200808050-00009.","journal-title":"Ann Intern Med"},{"key":"4994_CR11","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","volume":"360","author":"GL Andriole","year":"2009","unstructured":"Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD, Hsing AW, Lacey JV, Purdue M, Simpson NK, Cumberlin R, Plco Project Team, et al: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009, 360: 1310-1319. 10.1056\/NEJMoa0810696.","journal-title":"N Engl J Med"},{"key":"4994_CR12","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1200\/JCO.2001.19.16.3692","volume":"19","author":"DI Quinn","year":"2001","unstructured":"Quinn DI, Henshall SM, Haynes AM, Brenner PC, Kooner R, Golovsky D, Mathews J, O\u2019Neill GF, Turner JJ, Delprado W, Finlayson JF, Sutherland RL, Grygiel JJ, Stricker PD: Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol. 2001, 19: 3692-3705.","journal-title":"J Clin Oncol"},{"key":"4994_CR13","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1002\/cncr.24348","volume":"115","author":"M Roach 3rd","year":"2009","unstructured":"Roach M, Waldman F, Pollack A: Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer. 2009, 115: 3112-3120. 10.1002\/cncr.24348.","journal-title":"Cancer"},{"key":"4994_CR14","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3109\/0284186X.2010.499371","volume":"49","author":"AS Ishkanian","year":"2010","unstructured":"Ishkanian AS, Zafarana G, Thoms J, Bristow RG: Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer. Acta Oncol (Stockholm, Sweden). 2010, 49: 888-894. 10.3109\/0284186X.2010.499371.","journal-title":"Acta Oncol (Stockholm, Sweden)"},{"key":"4994_CR15","doi-asserted-by":"publisher","first-page":"465179","DOI":"10.1155\/2013\/465179","volume":"2013","author":"A Fernandez-Serra","year":"2013","unstructured":"Fernandez-Serra A, Rubio L, Calatrava A, Rubio-Briones J, Salgado R, Gil-Benso R, Espinet B, Garcia-Casado Z, Lopez-Guerrero JA: Molecular characterization and clinical impact of TMPRSS2-ERG rearrangement on prostate cancer: comparison between FISH and RT-PCR. BioMed Res Int. 2013, 2013: 465179-","journal-title":"BioMed Res Int"},{"key":"4994_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/1748-717X-5-108","volume":"5","author":"J Rudner","year":"2010","unstructured":"Rudner J, Ruiner C-E, Handrick R, Eibl H-J, Belka C, Jendrossek V: The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiat Oncol (London, England). 2010, 5: 108-10.1186\/1748-717X-5-108.","journal-title":"Radiat Oncol (London, England)"},{"key":"4994_CR17","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1038\/sj.onc.1209186","volume":"25","author":"S Josson","year":"2006","unstructured":"Josson S, Xu Y, Fang F, Dhar SK, St Clair DK, St Clair WH: RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Oncogene. 2006, 25: 1554-1559. 10.1038\/sj.onc.1209186.","journal-title":"Oncogene"},{"key":"4994_CR18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1158\/0008-5472.CAN-07-2120","volume":"68","author":"SA Amundson","year":"2008","unstructured":"Amundson SA, Do KT, Vinikoor LC, Lee RA, Koch-Paiz CA, Ahn J, Reimers M, Chen Y, Scudiero DA, Weinstein JN, Trent JM, Bittner ML, Meltzer PS, Fornace AJ: Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res. 2008, 68: 415-424. 10.1158\/0008-5472.CAN-07-2120.","journal-title":"Cancer Res"},{"key":"4994_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/nar\/gki161","volume":"33","author":"KH Brettingham-Moore","year":"2005","unstructured":"Brettingham-Moore KH, Rao S, Juelich T, Shannon MF, Holloway AF: GM-CSF promoter chromatin remodelling and gene transcription display distinct signal and transcription factor requirements. Nucleic Acids Res. 2005, 33: 225-234. 10.1093\/nar\/gki161.","journal-title":"Nucleic Acids Res"},{"key":"4994_CR20","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1093\/nar\/gkn171","volume":"36","author":"JY Park","year":"2008","unstructured":"Park JY, Yoo HW, Kim BR, Park R, Choi SY, Kim Y: Identification of a novel human Rad51 variant that promotes DNA strand exchange. Nucleic Acids Res. 2008, 36: 3226-3234. 10.1093\/nar\/gkn171.","journal-title":"Nucleic Acids Res"},{"key":"4994_CR21","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1073\/pnas.0904783107","volume":"107","author":"DC Hegan","year":"2010","unstructured":"Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS, Glazer PM: Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci U S A. 2010, 107: 2201-2206. 10.1073\/pnas.0904783107.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4994_CR22","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1111\/j.1464-410X.2010.09833.x","volume":"107","author":"CN Anandadas","year":"2011","unstructured":"Anandadas CN, Clarke NW, Davidson SE, O\u2019Reilly PH, Logue JP, Gilmore L, Swindell R, Brough RJ, Wemyss-Holden GD, Lau MW, Javle PM, Ramani VA, Wylie JP, Collins GN, Brown S, Cowan RA: Early prostate cancer\u2013which treatment do men prefer and why?. BJU Int. 2011, 107: 1762-1768. 10.1111\/j.1464-410X.2010.09833.x.","journal-title":"BJU Int"},{"key":"4994_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.urology.2007.03.060","volume":"70","author":"MJ Zelefsky","year":"2007","unstructured":"Zelefsky MJ, Kattan MW, Fearn P, Fearon BL, Stasi JP, Shippy AM, Scardino PT: Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Urology. 2007, 70: 283-287.","journal-title":"Urology"},{"key":"4994_CR24","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/jcp.2002.003954","volume":"58","author":"C Hughes","year":"2005","unstructured":"Hughes C, Murphy A, Martin C, Sheils O, O\u2019Leary J: Molecular pathology of prostate cancer. J Clin Pathol. 2005, 58: 673-684. 10.1136\/jcp.2002.003954.","journal-title":"J Clin Pathol"},{"key":"4994_CR25","first-page":"183","volume":"25","author":"L Trojan","year":"2005","unstructured":"Trojan L, Schaaf A, Steidler A, Haak M, Thalmann G, Knoll T, Gretz N, Alken P, Michel MS: Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. Anticancer Res. 2005, 25: 183-191.","journal-title":"Anticancer Res"},{"key":"4994_CR26","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/S1470-2045(05)70246-1","volume":"6","author":"KM Prise","year":"2005","unstructured":"Prise KM, Schettino G, Folkard M, Held KD: New insights on cell death from radiation exposure. Lancet Oncol. 2005, 6: 520-528. 10.1016\/S1470-2045(05)70246-1.","journal-title":"Lancet Oncol"},{"key":"4994_CR27","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1080\/02841860152619115","volume":"40","author":"RA Gatti","year":"2001","unstructured":"Gatti RA: The inherited basis of human radiosensitivity. Acta Oncol. 2001, 40: 702-711. 10.1080\/02841860152619115.","journal-title":"Acta Oncol"},{"key":"4994_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00240-003-0299-0","volume":"31","author":"AM Serafin","year":"2003","unstructured":"Serafin AM, Akudugu JM, Bohm L: Studies on the influence of DNA repair on radiosensitivity in prostate cell lines. Urol Res. 2003, 31: 227-231. 10.1007\/s00240-003-0299-0.","journal-title":"Urol Res"},{"key":"4994_CR29","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1080\/09553000050176252","volume":"76","author":"WP Roos","year":"2000","unstructured":"Roos WP, Binder A, Bohm L: Determination of the initial DNA damage and residual DNA damage remaining after 12\u00a0hours of repair in eleven cell lines at low doses of irradiation. Int J Radiat Biol. 2000, 76: 1493-1500. 10.1080\/09553000050176252.","journal-title":"Int J Radiat Biol"},{"key":"4994_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/bjc.1995.62","volume":"71","author":"MI Nunez","year":"1995","unstructured":"Nunez MI, Villalobos M, Olea N, Valenzuela MT, Pedraza V, McMillan TJ, de Almodovar JMR: Radiation-induced DNA double-strand break rejoining in human tumour cells. Br J Cancer. 1995, 71: 311-316. 10.1038\/bjc.1995.62.","journal-title":"Br J Cancer"},{"key":"4994_CR31","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/JTO.0b013e318244bdd4","volume":"7","author":"C Papadaki","year":"2012","unstructured":"Papadaki C, Sfakianaki M, Ioannidis G, Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J: ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. J Thorac Oncol. 2012, 7: 663-671. 10.1097\/JTO.0b013e318244bdd4.","journal-title":"J Thorac Oncol"},{"key":"4994_CR32","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1158\/1535-7163.MCT-07-2432","volume":"7","author":"JA Casado","year":"2008","unstructured":"Casado JA, Rio P, Marco E, Garcia-Hernandez V, Domingo A, Perez L, Tercero JC, Vaquero JJ, Albella B, Gago F, Bueren JA: Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol Cancer Ther. 2008, 7: 1309-1318. 10.1158\/1535-7163.MCT-07-2432.","journal-title":"Mol Cancer Ther"},{"key":"4994_CR33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.gene.2012.05.037","volume":"504","author":"A Nogueira","year":"2012","unstructured":"Nogueira A, Catarino R, Faustino I, Nogueira-Silva C, Figueiredo T, Lombo L, Hilario-Silva I, Pereira D, Medeiros R: Role of the RAD51 G172T polymorphism in the clinical outcome of cervical cancer patients under concomitant chemoradiotherapy. Gene. 2012, 504: 279-283. 10.1016\/j.gene.2012.05.037.","journal-title":"Gene"},{"key":"4994_CR34","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/j.1349-7006.2004.tb02195.x","volume":"95","author":"K Yoshida","year":"2004","unstructured":"Yoshida K, Miki Y: Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004, 95: 866-871. 10.1111\/j.1349-7006.2004.tb02195.x.","journal-title":"Cancer Sci"},{"key":"4994_CR35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1046\/j.0022-202X.2004.22212.x","volume":"122","author":"C Hesling","year":"2004","unstructured":"Hesling C, D\u2019Incan M, D\u2019Incan C, Souteyrand P, Monboisse J-C, Pasco S, Madelmont J-C, Bignon YJ: Downregulation of BRCA1 in A375 melanoma cell line increases radio-sensitivity and modifies metastatic and angiogenic gene expression. J Invest Dermatol. 2004, 122: 369-380. 10.1046\/j.0022-202X.2004.22212.x.","journal-title":"J Invest Dermatol"},{"key":"4994_CR36","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1038\/sj.onc.1206319","volume":"22","author":"C Zhou","year":"2003","unstructured":"Zhou C, Smith JL, Liu J: Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene. 2003, 22: 2396-2404. 10.1038\/sj.onc.1206319.","journal-title":"Oncogene"},{"key":"4994_CR37","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1158\/0008-5472.CAN-09-1477","volume":"70","author":"A De Siervi","year":"2010","unstructured":"De Siervi A, De Luca P, Byun JS, Di LJ, Fufa T, Haggerty CM, Vazquez E, Moiola C, Longo DL, Gardner K: Transcriptional autoregulation by BRCA1. Cancer Res. 2010, 70: 532-542. 10.1158\/0008-5472.CAN-09-1477.","journal-title":"Cancer Res"},{"key":"4994_CR38","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1074\/jbc.275.6.4532","volume":"275","author":"A Wang","year":"2000","unstructured":"Wang A, Schneider-Broussard R, Kumar AP, MacLeod MC, Johnson DG: Regulation of BRCA1 expression by the Rb-E2F pathway. J Biol Chem. 2000, 275: 4532-4536. 10.1074\/jbc.275.6.4532.","journal-title":"J Biol Chem"},{"key":"4994_CR39","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/j.bbamcr.2008.05.006","volume":"1783","author":"I Mallik","year":"2008","unstructured":"Mallik I, Davila M, Tapia T, Schanen B, Chakrabarti R: Androgen regulates Cdc6 transcription through interactions between androgen receptor and E2F transcription factor in prostate cancer cells. Biochim Biophys Acta. 2008, 1783: 1737-1744. 10.1016\/j.bbamcr.2008.05.006.","journal-title":"Biochim Biophys Acta"},{"key":"4994_CR40","first-page":"589","volume":"26","author":"L Hasselbach","year":"2005","unstructured":"Hasselbach L, Haase S, Fischer D, Kolberg HC, Sturzbecher HW: Characterisation of the promoter region of the human DNA-repair gene Rad51. Eur J Gynaecol Oncol. 2005, 26: 589-598.","journal-title":"Eur J Gynaecol Oncol"},{"key":"4994_CR41","first-page":"1809","volume":"43","author":"JS Horoszewicz","year":"1983","unstructured":"Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res. 1983, 43: 1809-1818.","journal-title":"Cancer Res"},{"key":"4994_CR42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/pros.2990230206","volume":"23","author":"AG Carroll","year":"1993","unstructured":"Carroll AG, Voeller HJ, Sugars L, Gelmann EP: p53 oncogene mutations in three human prostate cancer cell lines. Prostate. 1993, 23: 123-134. 10.1002\/pros.2990230206.","journal-title":"Prostate"},{"key":"4994_CR43","first-page":"16","volume":"17","author":"ME Kaighn","year":"1979","unstructured":"Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Investig Urol. 1979, 17: 16-23.","journal-title":"Investig Urol"},{"key":"4994_CR44","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0022-5347(01)66165-2","volume":"155","author":"NJ Prendergast","year":"1996","unstructured":"Prendergast NJ, Atkins MR, Schatte EC, Paulson DF, Walther PJ: p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. J Urol. 1996, 155: 1685-1692. 10.1016\/S0022-5347(01)66165-2.","journal-title":"J Urol"},{"key":"4994_CR45","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/S0360-3016(02)02781-5","volume":"53","author":"MA Ritter","year":"2002","unstructured":"Ritter MA, Gilchrist KW, Voytovich M, Chappell RJ, Verhoven BM: The role of p53 in radiation therapy outcomes for favorable-to-intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2002, 53: 574-580. 10.1016\/S0360-3016(02)02781-5.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4994_CR46","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S0090-4295(97)00636-5","volume":"51","author":"A Huang","year":"1998","unstructured":"Huang A, Gandour-Edwards R, Rosenthal SA, Siders DB, Deitch AD, White RW: p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology. 1998, 51: 346-351. 10.1016\/S0090-4295(97)00636-5.","journal-title":"Urology"},{"key":"4994_CR47","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/0360-3016(96)00134-4","volume":"35","author":"P Stattin","year":"1996","unstructured":"Stattin P, Damber JE, Modig H, Bergh A: Pretreatment p53 immunoreactivity does not infer radioresistance in prostate cancer patients. Int J Radiat Oncol Biol Phys. 1996, 35: 885-889. 10.1016\/0360-3016(96)00134-4.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4994_CR48","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1056\/NEJM199904153401503","volume":"340","author":"HM Keys","year":"1999","unstructured":"Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, Walker JL, Gersell D: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999, 340: 1154-1161. 10.1056\/NEJM199904153401503.","journal-title":"N Engl J Med"},{"key":"4994_CR49","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2214\/ajr.126.2.229","volume":"126","author":"TC Lo","year":"1976","unstructured":"Lo TC, Wiley AL, Ansfield FJ, Brandenburg JH, Davis HL, Gollin FF, Johnson RO, Ramirez G, Vermund H: Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. AJR Am J Roentgenol. 1976, 126: 229-235. 10.2214\/ajr.126.2.229.","journal-title":"AJR Am J Roentgenol"},{"key":"4994_CR50","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1002\/cncr.2820360915","volume":"36","author":"V Vongtama","year":"1975","unstructured":"Vongtama V, Douglass HO, Moore RH, Holyoke ED, Webster JH: End results of radiation therapy, alone and combination with 5-fluorouracil in colorectal cancers. Cancer. 1975, 36: 2020-2025. 10.1002\/cncr.2820360915.","journal-title":"Cancer"},{"key":"4994_CR51","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(00)00387-9","volume":"2","author":"J Jassem","year":"2001","unstructured":"Jassem J: Combined chemotherapy and radiation in locally advanced non-small-cell lung cancer. Lancet Oncol. 2001, 2: 335-342. 10.1016\/S1470-2045(00)00387-9.","journal-title":"Lancet Oncol"},{"key":"4994_CR52","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/0005-2787(71)90012-8","volume":"238","author":"JB Clark","year":"1971","unstructured":"Clark JB, Ferris GM, Pinder S: Inhibition of nuclear NAD nucleosidase and poly ADP-ribose polymerase activity from rat liver by nicotinamide and 5\u2032-methyl nicotinamide. Biochim Biophys Acta. 1971, 238: 82-85. 10.1016\/0005-2787(71)90012-8.","journal-title":"Biochim Biophys Acta"},{"key":"4994_CR53","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nbt.2121","volume":"30","author":"E Wahlberg","year":"2012","unstructured":"Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell A-G, Pol E, Frostell A, Ekblad T, Oncu D, Kull B, Robertson GM, Pellicciari R, Schuler H, Weigelt J: Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol. 2012, 30: 283-288. 10.1038\/nbt.2121.","journal-title":"Nat Biotechnol"},{"key":"4994_CR54","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","volume":"376","author":"A Tutt","year":"2010","unstructured":"Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010, 376: 235-244. 10.1016\/S0140-6736(10)60892-6.","journal-title":"Lancet"},{"key":"4994_CR55","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","volume":"376","author":"MW Audeh","year":"2010","unstructured":"Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010, 376: 245-251. 10.1016\/S0140-6736(10)60893-8.","journal-title":"Lancet"},{"key":"4994_CR56","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","volume":"28","author":"PC Fong","year":"2010","unstructured":"Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB: Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010, 28: 2512-2519. 10.1200\/JCO.2009.26.9589.","journal-title":"J Clin Oncol"},{"key":"4994_CR57","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","volume":"13","author":"CK Donawho","year":"2007","unstructured":"Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, Hristov B, Idler KB, Jarvis K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC, McGonigal TP, Meulbroek JA, Olson AM, Palma JP, Rodriguez LE, et al: ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007, 13: 2728-2737. 10.1158\/1078-0432.CCR-06-3039.","journal-title":"Clin Cancer Res"},{"key":"4994_CR58","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1124\/jpet.107.120758","volume":"324","author":"AA Sauve","year":"2008","unstructured":"Sauve AA: NAD\u2009+\u2009and vitamin B3: from metabolism to therapies. J Pharmacol Exp Ther. 2008, 324: 883-893.","journal-title":"J Pharmacol Exp Ther"},{"key":"4994_CR59","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1158\/1535-7163.MCT-08-0959","volume":"8","author":"A Choudhury","year":"2009","unstructured":"Choudhury A, Zhao H, Jalali F, Al Rashid S, Ran J, Supiot S, Kiltie AE, Bristow RG: Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol Cancer Ther. 2009, 8: 203-213. 10.1158\/1535-7163.MCT-08-0959.","journal-title":"Mol Cancer Ther"},{"key":"4994_CR60","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/0008-5472.CAN-12-1170","volume":"73","author":"B Qiao","year":"2013","unstructured":"Qiao B, Kerr M, Groselj B, Teo MTW, Knowles MA, Bristow RG, Phillips RM, Kiltie AE: Imatinib radiosensitizes bladder cancer by targeting homologous recombination. Cancer Res. 2013, 73: 1611-1620. 10.1158\/0008-5472.CAN-12-1170.","journal-title":"Cancer Res"},{"key":"4994_CR61","first-page":"7377","volume":"63","author":"JS Russell","year":"2003","unstructured":"Russell JS, Brady K, Burgan WE, Cerra MA, Oswald KA, Camphausen K, Tofilon PJ: Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res. 2003, 63: 7377-7383.","journal-title":"Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-808.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-14-808\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-808.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T06:25:34Z","timestamp":1630563934000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-14-808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,4]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["4994"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-14-808","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,4]]},"assertion":[{"value":"2 June 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"808"}}